載入中
Microbot Medical Inc. operates as a pre-clinical stage medical device company, concentrating its efforts on the research, design, and development of robotic instruments for endoluminal surgery, specifically targeting the field of minimally invasive procedures. Leveraging its proprietary micro-robotic technologies, which include ViRob, TipCAT, CardioSert, and Liberty, the company is actively developing several key products. These include a Self-Cleaning Shunt intended for the treatment of hydrocephalus and normal pressure hydrocephalus, as well as a single-use robotic system designed for various endovascular interventional applications. Additionally, Microbot Medical maintains a robust, multi-generational product pipeline. Its global intellectual property portfolio is substantial, encompassing 42 granted or allowed patents and an additional 23 patent applications currently under review. The company also benefits from a strategic collaboration agreement with Stryker Corporation, focusing on joint technology development. Established in 2010, Microbot Medical Inc. is headquartered in Hingham, Massachusetts.
前收盤價
US$1.04
−US$0.03 · -2.80%
盤後
US$1.04
US$0.00 · 0.00%
10月12日 下午7:54 ET
盤中時間採用ET。市場資料可能有所延遲。
Microbot Medical Inc. operates as a pre-clinical stage medical device company, concentrating its efforts on the research, design, and development of robotic instruments for endoluminal surgery, specifically targeting the field of minimally invasive procedures. Leveraging its proprietary micro-robotic technologies, which include ViRob, TipCAT, CardioSert, and Liberty, the company is actively developing several key products. These include a Self-Cleaning Shunt intended for the treatment of hydrocephalus and normal pressure hydrocephalus, as well as a single-use robotic system designed for various endovascular interventional applications. Additionally, Microbot Medical maintains a robust, multi-generational product pipeline. Its global intellectual property portfolio is substantial, encompassing 42 granted or allowed patents and an additional 23 patent applications currently under review. The company also benefits from a strategic collaboration agreement with Stryker Corporation, focusing on joint technology development. Established in 2010, Microbot Medical Inc. is headquartered in Hingham, Massachusetts.
日內區間
目前US$1.04
52週區間
目前US$1.04
盤中時間採用ET。市場資料可能有所延遲。
Microbot Medical Inc. operates as a pre-clinical stage medical device company, concentrating its efforts on the research, design, and development of robotic instruments for endoluminal surgery, specifically targeting the field of minimally invasive procedures. Leveraging its proprietary micro-robotic technologies, which include ViRob, TipCAT, CardioSert, and Liberty, the company is actively developing several key products. These include a Self-Cleaning Shunt intended for the treatment of hydrocephalus and normal pressure hydrocephalus, as well as a single-use robotic system designed for various endovascular interventional applications. Additionally, Microbot Medical maintains a robust, multi-generational product pipeline. Its global intellectual property portfolio is substantial, encompassing 42 granted or allowed patents and an additional 23 patent applications currently under review. The company also benefits from a strategic collaboration agreement with Stryker Corporation, focusing on joint technology development. Established in 2010, Microbot Medical Inc. is headquartered in Hingham, Massachusetts.
日內區間
目前US$1.04
52週區間
目前US$1.04
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | — | 9.1萬 USD | 10.6萬 USD | — | — |
| 毛利 | — | −9.1萬 USD | −10.6萬 USD | — | — |
| 研究與開發 | 628.3萬 USD | 663萬 USD | 572.4萬 USD | 773.6萬 USD | 615.3萬 USD |
| 銷售、一般及管理費用 | 824.7萬 USD | 499.5萬 USD | 413.1萬 USD | 558.1萬 USD | 541萬 USD |
| 營業費用 | 1474.3萬 USD | 1153.4萬 USD | 974.9萬 USD | 1328.1萬 USD | 1135.7萬 USD |
| 利息收入 | 128.5萬 USD | 18.2萬 USD | 22.8萬 USD | 5.4萬 USD | 4.4萬 USD |
| 折舊和攤銷 | 4.7萬 USD | 9.1萬 USD | 10.6萬 USD | 10.2萬 USD | 7.6萬 USD |
| 營業利益 | −1474.3萬 USD | −1162.5萬 USD | −985.5萬 USD | −1328.1萬 USD | −1135.7萬 USD |
| 淨利 | −1314.2萬 USD | −1144.3萬 USD | −1074萬 USD | −1316.8萬 USD | −1131.3萬 USD |
公司資料更新於 2026年10月13日。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$4.00
上漲空間 284.62%評級樣本有限，僅4項
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2018年9月5日 | 1:15 | — | — |
股票分割 | 2016年11月29日 | 1:9 | — | — |
股票分割 | 2016年5月9日 | 1:12 | — | — |
股票分割 | 2011年7月6日 | 1:10 | — | — |
已生效 2018年9月5日
1:15
已生效 2016年11月29日
1:9
已生效 2016年5月9日
1:12
已生效 2011年7月6日
1:10
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI314.37萬0.00%2.3兆 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF111.96萬0.00%954億 USD0.05%US$233.52-0.63%
iShares Micro-Cap ETFIWC23.41萬0.02%13.17億 USD0.60%US$181.66-0.73%
Invesco NASDAQ Future Gen 200 ETFQQQS8.62萬0.38%2275.83萬 USD0.20%US$41.414-1.73%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCInvesco NASDAQ Future Gen 200 ETFQQQSAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
